PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 487/04, A61K 31/505 // (C07D 487/04, 239:00, 239:00) — A1

(11) International Publication Number: **WO 00/24744**

(43) International Publication Date: 4 May 2000 (04.05.00)

(21) International Application Number: PCT/EP99/07675

(22) International Filing Date: 13 October 1999 (13.10.99)

(30) Priority Data:

9823277.0	23 October 1998 (23.10.98)	GB
9920044.6	24 August 1999 (24.08.99)	GB

(71) Applicant: F. HOFFMANN–LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH–4002 Basle (CH).


(72) Inventors: HARRIS, William; 8 Fakeswell Lane, Lower Stondon, Henlow, Bedfordshire SG16 6JY (GB). HILL, Christopher, Huw; 8 Penfold Close, Baldock, Hertfordshire SG7 6UT (GB). SMITH, Ian, Edward, David; 5 Church Road, Wellington, Bedfordshire MK44 3QD (GB).

(74) Agent: LOESCHNER, Thomas; Grenzacherstrasse 124, CH–4070 Basle (CH).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: BICYCLIC NITROGEN HETEROCYCLES



(I)

(57) Abstract

Amino–substituted dihydropyrimido [4,5–d]pyrimidinones of formula (I) in which R^1 represents hydrogen, lower alkyl, aryl, aryl–lower alkyl, heteroaryl, heteroaryl–lower alkyl, lower cycloalkyl or lower cycloalkyl–lower alkyl, R^2 represents lower alkyl, aryl, aryl–lower alkyl, heteroaryl, heteroaryl–lower alkyl, lower cycloalkyl or lower cycloalkyl–lower alkyl; and R^3 represents hydrogen, lower alkyl, aryl, aryl–lower alkyl, heteroaryl, heteroaryl–lower alkyl, lower cycloalkyl, lower cycloalkenyl or lower cycloalkyl–lower alkyl, and pharmaceutically acceptable salts thereof are protein kinase inhibitors. They can be used in the treatment or prophylaxis of inflammatory, immunological, oncological, bronchopulmonary, dermatological and cardiovascular disorders, in the treatment of asthma, central nervous system disorders or diabetic complications or for the prevention of graft rejection following transplant surgery.